What HIV Vaccine Preparedness Teaches us about COVID Vaccine Distribution

What HIV Vaccine Preparedness Teaches us about COVID Vaccine Distribution

I recently found a 1995 presentation with findings from my doctoral dissertation that are highly pertinent to COVID Vaccine trials. The study included anonymized interviews and surveys with the first high risk (#vulnerable) HIV vaccine efficacy trial participants.

No space here to share the results but I thought readers would find the questions of interest:
–Motivations for joining the trial (altruism, money, protection, access to HIV tests);
–Understanding about the vaccine trial protocol, e.g. likelihood of getting a placebo or ineffective vaccine;
–Belief they got the vaccine or placebo and reason for belief;
–Accuracy of their belief in relation to actual vaccine assignment group;
–HIV risk behaviors before and during the trial;
–Accuracy of HIV risk disclosure to vaccine trial staff;
–Receipt of HIV tests outside of the trial (e.g. unblinding them);
–Social harms/discriminatory events (e.g. due to having a vaccine-induced positive HIV test).

The study findings led to adoption of some procedures for all subsequent HIV vaccine trials such as requiring subjects to demonstrate their understanding of the risks.

Wonder whether #COVID#vaccine trials are doing that now? How are they assessing COVID-related risks and COVID-testing outside of the trial?